Interplay of serum hepcidin with female sex hormones, metabolic syndrome, and abdominal fat distribution among premenopausal and postmenopausal women

The Egyptian Journal of Internal Medicine

Table 3 Association of serum hepcidin and metabolic syndrome (MetS)

*A-Association of MetS % and hepcidin quartiles (Qs)***
	Premenopausal				Post-menopause
Hepcidin Qs	Q1(n = 24)	Q2(n = 24)	Q3(n = 24)	Q4(n = 24)	Q1(n = 16)	Q2(n = 16)		Q3(n = 16)	Q4(n = 16)
MetS n (%)	0(0%)	9(37.5%)	12(50%)	24(100%)	0(0%)	10(62.5%)		10(62.5%)	16(100%)
P value	< 0.001				< 0.001
B-Association of serum hepcidin (ng/ml) with MetS features’ number
MetS features (n)	Premenopausal					Post-menopause
MetS features (n)	0	1	2	3	4	1	2	3	4
Subjects (n)	12	6	33	27	18	8	20	14	22
Hepcidin level	3.2 ± 0.6	4.0 ± 0.7	5.6 ± 1.8	7.8 ± 1.9	9.4 ± 1.6	7.6 ± 0.6	10.7 ± 2.5	12.6 ± 1.8	16.6 ± 2.6
P value	< 0.001					< 0.001
C-ROC curve analysis of hepcidin (ng/ml) for prediction of metabolic syndrome
	Optimal cutoff	AUC	P value	Sensitivity	Specificity	PPV		NPV	Accuracy
Premenopausal	≥ 5.8	0.910	< 0.001	93.3	76.5	77.8		92.9	84.4
Postmenopausal	≥ 10.3	0.907	< 0.001	100	71.4	81.8		100	87.5

Bold: significant at p value < 0.05
AUC Area under the curve, PPV Positive predictive value, NPV Negative predictive value